BIIB Soars: New Chief Legal Officer Appointed!
📈 Stock jumped after appointing Michael J. Parini as Chief Legal Officer effective August 3, 2026, bringing 20+ years of experience from Pfizer and Vertex.
📉 Revenue declined from ~$11.0 billion in 2021 to $9.84 billion in 2023 due to patent expirations on legacy multiple-sclerosis drugs.
💊 Leqembi (lecanemab) received full FDA approval in 2023 and saw a 56% jump in U.S. prescriptions in one month by early 2024.
🤝 Biogen and partner Eisai share costs and profits 50/50 on Leqembi, with European approval expected by 2025.
💰 Company guided roughly flat sales for 2024 as new product revenues only starting to offset legacy declines.
🏥 Acquired Reata Pharmaceuticals in late 2023 to obtain Skyclarys, contributing $55.9 million in U.S. sales in Q4 2023.
💸 Biogen paused share buybacks in 2023, leaving ~$2.1 billion authorized but unused under its program as of Dec 31, 2023.
📉 Long-term debt stands at $6.79 billion with the nearest major maturity of $1.75 billion due in September 2025.
🏦 Moody's affirmed Biogen's Baa2 credit rating and S&P rates its unsecured notes BBB+ as of April 2026.
⚖️ Company has never paid a cash dividend and explicitly states no current intention to start paying dividends.
⚠️ Faces declining sales from Spinraza due to competition from Novartis' gene therapy and Roche's oral drug.
🥊 Intense competition in Alzheimer's treatment with Eli Lilly's donanemab (Kisunla) FDA-approved in 2024.
⚖️ Agreed to pay $900 million to settle a DOJ False Claims Act lawsuit in 2022 regarding kickbacks to doctors.
📉 Zurzuvæ received FDA approval only for postpartum depression, not the larger major depressive disorder indication.
🔬 Biogen's operating costs fell ~17% in Q4 2022 under CEO Christopher Viehbacher's cost-cutting measures.
- Stock price jumped following the appointment of a high-caliber Chief Legal Officer with deep industry expertise.
- Leqembi achieved full FDA approval in 2023 and demonstrated rapid initial uptake with a 56% jump in prescriptions in one month.
- Biogen maintains an investment-grade credit rating (Moody's Baa2, S&P BBB+) reflecting a manageable leverage profile.
- Company generated net interest income of $29.6 million in 2023 as rising rates turned it into a net interest income position.
- CEO Christopher Viehbacher successfully reduced operating costs by ~17% in Q4 2022, helping boost profit margins.
- Biogen retains ample financial flexibility with a $1.0 billion unutilized revolving credit line for liquidity.
- Acquisition of Reata Pharmaceuticals secured Skyclarys, the first approved treatment for Friedreich's ataxia.
- Revenue has been trending down from ~$11.0 billion in 2021 to $9.84 billion in 2023 due to patent expirations and competition.
- Biogen guided roughly flat sales for 2024, indicating new product revenues are only just starting to offset legacy declines.
- Company paused share buybacks in 2023, leaving approximately $2.1 billion authorized but unused under the program.
- Legacy multiple-sclerosis drugs face steep sales erosion from generics and biosimilars, including Tecfidera losing exclusivity.
- Spinraza sales are declining due to competition from Novartis' gene therapy and Roche's oral drug.
- Leqembi faces intense competition as Eli Lilly's donanemab (Kisunla) was FDA-approved in 2024, splitting the market.
- Zurzuvæ received FDA approval only for postpartum depression, severely curbing its potential market size compared to major depressive disorder.
- Company paid a $900 million settlement in 2022 to resolve a DOJ False Claims Act lawsuit alleging kickbacks to doctors.
- Aduhelm was discontinued by early 2023 due to disappointing sales and ongoing controversy following its controversial launch.
- Zurzuvæ has a steep price of about $15,900 for a 2-week course, which could hinder insurance coverage and uptake.
- Biogen carries $6.79 billion in long-term debt with a significant $1.75 billion tranche due in September 2025.
